NCT07560943 — West China Hospital neoantigen vaccine trial
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
Registry record
| Registry ID | NCT07560943 ↗ |
|---|---|
| Lead sponsor | West China Hospital |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Cancer |
| Enrollment | 9 participants (target) |
| Start date | 2026-04-28 |
| Primary completion | 2027-04-28 (est.) |
| Last registry update | 11 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07560943), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07560943?
NCT07560943 (Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors) is registered on ClinicalTrials.gov as Phase 1, sponsored by West China Hospital.
Is NCT07560943 recruiting?
As of the 2026-05-11 registry update, NCT07560943 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07560943?
The lead sponsor is West China Hospital.
What condition does NCT07560943 study?
The registered condition is Cancer. Primary completion is listed as 2027-04-28 (estimated).
Are results available for NCT07560943?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07560943.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.